Global Congenital Neutropenia Treatment Market, By Type (Idiopathic, Cyclic, Autoimmune Neutropenia), Treatment (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure and Others), Route of Administration (renteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Congenital Neutropenia Treatment Market Analysis and Size
The congenital neutropenia treatment market is expected to witness significant growth during the forecast period. In 2014, approximately 1.6 million new cancer cases were registered in the U.S., and around 600,000 individuals died. The market is mainly driven by the high prevalence of cancer, where chemotherapy is the primary treatment, and also development of several promising pipeline drugs. Multiple treatment landscapes and effective diagnosis are considered positive indicators of the demand for the growth of the congenital neutropenia treatment market.
Data Bridge Market Research analyses a growth rate in the global congenital neutropenia treatment market in the forecast period 2023-2030. The expected CAGR of the global congenital neutropenia treatment market is around 5.90% in the mentioned forecast period. The market was valued at USD 15.03 million in 2022 and would grow to USD 23.77 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Congenital Neutropenia Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Idiopathic, Cyclic, Autoimmune Neutropenia), Treatment (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Ipsen Pharma (France), Spectrum Pharmaceuticals, Inc. (U.S.), Takeda Pharmaceutical Company Limited. (Japan)., BeyondSpring Inc. (U.S.)., Myelo Therapeutics GmbH (Germany)., Sandoz International GmbH (Switzerland), BioGenomics Limited. (India), Dr. Reddy's Laboratories Ltd. (India), Apotex Inc. (Canada)
|
|
Market Opportunities
|
|
Market Definition
Neutropenia is a rare disease in which a sudden decline in the level of neutrophils is witnessed, resulting in compromised immunity. Neutropenia can either be caused by several diseases or conditions such as chemotherapy, several infections, congenital bone marrow disorders, or autoimmune disorders, and also through specific drugs.
Global Congenital Neutropenia Treatment Market Dynamics
Drivers
- Increasing Demand for Targeted Therapy
The increasing demand for targeted therapy showed numerous advantages as it interferes with specific proteins involved in cancer, focusing on specific molecular changes that stop the growth of several cancers. Numerous major factors influenced the growth of uterine cancer, including the fewer adverse effects of the therapy and the availability of several targeted therapeutics. This boosts market growth.
- Growing R&D Activities
The latest introduction of small molecules is one of the major technologies that is gaining attraction globally in the market. The development of Plinabulin, a tiny chemical with immune-boosting properties created by BeyondSpring Pharmaceuticals, is projected to transform neutropenia treatment. In addition, Phase II tests have shown that this chemical has even more effective anti-cancer properties. This boosts market growth.
Opportunities
- Increase in Cancer Cases
The increasing occurrence of cancer is boosting the growth of the market. The frequency of patients with cancer in India among males was 679,421, and that for females was 712,758 for the year 2020. Cancer is a known cause of developing neutropenia. The primary treatment for cancer is chemotherapy and neutropenia can be caused by the extensive application of chemotherapy to the patients. Thus, it boosts market growth.
- Rising Healthcare Awareness
Health awareness amongst the population is rising, resulting in the prediction of drugs to boost the market growth. The substantial increase is attributed to a promising therapeutic pipeline that includes around five medicines in phase III clinical studies to treat neutropenia. The risk of neutropenia is expected to increase as the incidence of leukemia rises, predominantly after treatment. This creates more opportunities in the market.
Restraints/Challenges
- Side Effects of Chemotherapy
Several side effects are associated with chemotherapy. Effects such as anemia, sore mouth, hair loss, infections, and tiredness that are deeply affecting the patients and thus hampering the market growth.
- High Cost will Derail the Growth Rate
The huge expenditure on treatment methods hampers the market growth. Often, due to a lack of appropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options, which hampers their health. Thus, this is an important restrain that needs to be taken care of.
This global congenital neutropenia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global congenital neutropenia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Congenital Neutropenia Treatment Market Scope
The global congenital neutropenia treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Idiopathic
- Cyclic
- Autoimmune Neutropenia
Treatment
- Antibiotic Therapy
- Colony-Stimulating Factor Therapy
- Granulocyte Transfusion
- Splenectomy Procedure
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Congenital Neutropenia Treatment Market Regional Analysis/Insights
The global congenital neutropenia treatment market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global congenital neutropenia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to favorable healthcare infrastructure, high per capita income, and high rate of adoption of advanced surgeries in the region
Asia-Pacific dominates the market due to the huge promotion of research & development activities and awareness about the disease. Also, the huge number of leukaemia cases and the associated patients undergoing first-line chemotherapy treatment are also growing the market in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Congenital Neutropenia Treatment Market Share Analysis
The global congenital neutropenia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global congenital neutropenia treatment market.
Key players operating in the global congenital neutropenia treatment market include:
- Amgen Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Ipsen Pharma (France)
- Spectrum Pharmaceuticals, Inc. (U.S.)
- Takeda Pharmaceutical Company Limited. (Japan)
- BeyondSpring Inc. (U.S.).
- Myelo Therapeutics GmbH (Germany)
- Sandoz International GmbH (Switzerland)
- BioGenomics Limited.(India)
- Dr. Reddy's Laboratories Ltd. (India)
- Apotex Inc. (Canada)
SKU-